Logo image of HLN

HALEON PLC-ADR (HLN) Stock Fundamental Analysis

NYSE:HLN - New York Stock Exchange, Inc. - US4055521003 - ADR - Currency: USD

11.01  +0.1 (+0.92%)

After market: 11.01 0 (0%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to HLN. HLN was compared to 195 industry peers in the Pharmaceuticals industry. While HLN has a great profitability rating, there are some minor concerns on its financial health. HLN is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

HLN had positive earnings in the past year.
HLN had a positive operating cash flow in the past year.
Each year in the past 5 years HLN has been profitable.
In the past 5 years HLN always reported a positive cash flow from operatings.
HLN Yearly Net Income VS EBIT VS OCF VS FCFHLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

1.2 Ratios

Looking at the Return On Assets, with a value of 4.20%, HLN belongs to the top of the industry, outperforming 87.18% of the companies in the same industry.
HLN has a Return On Equity of 8.92%. This is amongst the best in the industry. HLN outperforms 87.18% of its industry peers.
With an excellent Return On Invested Capital value of 6.11%, HLN belongs to the best of the industry, outperforming 84.10% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for HLN is significantly below the industry average of 14.70%.
Industry RankSector Rank
ROA 4.2%
ROE 8.92%
ROIC 6.11%
ROA(3y)3.44%
ROA(5y)3.54%
ROE(3y)7.24%
ROE(5y)6.28%
ROIC(3y)6.15%
ROIC(5y)5.77%
HLN Yearly ROA, ROE, ROICHLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2 4 6 8

1.3 Margins

Looking at the Profit Margin, with a value of 12.84%, HLN belongs to the top of the industry, outperforming 89.74% of the companies in the same industry.
In the last couple of years the Profit Margin of HLN has grown nicely.
HLN has a Operating Margin of 21.31%. This is amongst the best in the industry. HLN outperforms 87.69% of its industry peers.
HLN's Operating Margin has improved in the last couple of years.
With a decent Gross Margin value of 60.75%, HLN is doing good in the industry, outperforming 70.26% of the companies in the same industry.
HLN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 21.31%
PM (TTM) 12.84%
GM 60.75%
OM growth 3Y-0.45%
OM growth 5Y3.75%
PM growth 3Y-4.12%
PM growth 5Y10.69%
GM growth 3Y0.43%
GM growth 5Y0.58%
HLN Yearly Profit, Operating, Gross MarginsHLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so HLN is destroying value.
HLN has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, HLN has less shares outstanding
The debt/assets ratio for HLN is higher compared to a year ago.
HLN Yearly Shares OutstandingHLN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B
HLN Yearly Total Debt VS Total AssetsHLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

An Altman-Z score of 2.42 indicates that HLN is not a great score, but indicates only limited risk for bankruptcy at the moment.
HLN has a Altman-Z score of 2.42. This is in the better half of the industry: HLN outperforms 70.77% of its industry peers.
HLN has a debt to FCF ratio of 5.11. This is a neutral value as HLN would need 5.11 years to pay back of all of its debts.
HLN's Debt to FCF ratio of 5.11 is amongst the best of the industry. HLN outperforms 83.08% of its industry peers.
HLN has a Debt/Equity ratio of 0.53. This is a neutral value indicating HLN is somewhat dependend on debt financing.
HLN's Debt to Equity ratio of 0.53 is on the low side compared to the rest of the industry. HLN is outperformed by 61.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF 5.11
Altman-Z 2.42
ROIC/WACC0.78
WACC7.83%
HLN Yearly LT Debt VS Equity VS FCFHLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.3 Liquidity

HLN has a Current Ratio of 0.98. This is a bad value and indicates that HLN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.98, HLN is doing worse than 83.59% of the companies in the same industry.
A Quick Ratio of 0.78 indicates that HLN may have some problems paying its short term obligations.
HLN has a Quick ratio of 0.78. This is amonst the worse of the industry: HLN underperforms 83.59% of its industry peers.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.78
HLN Yearly Current Assets VS Current LiabilitesHLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 6.59% over the past year.
HLN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 17.56% yearly.
The Revenue has decreased by -0.61% in the past year.
The Revenue has been growing slightly by 5.78% on average over the past years.
EPS 1Y (TTM)6.59%
EPS 3Y1.58%
EPS 5Y17.56%
EPS Q2Q%32.07%
Revenue 1Y (TTM)-0.61%
Revenue growth 3Y5.58%
Revenue growth 5Y5.78%
Sales Q2Q%-0.25%

3.2 Future

The Earnings Per Share is expected to grow by 8.61% on average over the next years. This is quite good.
Based on estimates for the next years, HLN will show a small growth in Revenue. The Revenue will grow by 3.97% on average per year.
EPS Next Y9.06%
EPS Next 2Y8.99%
EPS Next 3Y8.81%
EPS Next 5Y8.61%
Revenue Next Year0.74%
Revenue Next 2Y2.54%
Revenue Next 3Y3.21%
Revenue Next 5Y3.97%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
HLN Yearly Revenue VS EstimatesHLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
HLN Yearly EPS VS EstimatesHLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 0.1 0.2 0.3 0.4 0.5

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 22.02, which indicates a rather expensive current valuation of HLN.
Based on the Price/Earnings ratio, HLN is valued cheaply inside the industry as 82.56% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.60. HLN is around the same levels.
HLN is valuated rather expensively with a Price/Forward Earnings ratio of 20.36.
75.38% of the companies in the same industry are more expensive than HLN, based on the Price/Forward Earnings ratio.
HLN's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.39.
Industry RankSector Rank
PE 22.02
Fwd PE 20.36
HLN Price Earnings VS Forward Price EarningsHLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, HLN is valued cheaper than 81.03% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, HLN is valued cheaper than 84.10% of the companies in the same industry.
Industry RankSector Rank
P/FCF 18.4
EV/EBITDA 16.32
HLN Per share dataHLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
HLN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.43
PEG (5Y)1.25
EPS Next 2Y8.99%
EPS Next 3Y8.81%

More info and screens

3

5. Dividend

5.1 Amount

HLN has a Yearly Dividend Yield of 1.64%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 4.16, HLN pays a better dividend. On top of this HLN pays more dividend than 91.28% of the companies listed in the same industry.
Compared to the average S&P500 Dividend Yield of 2.39, HLN is paying slightly less dividend.
Industry RankSector Rank
Dividend Yield 1.64%

5.2 History

HLN has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of HLN decreased recently.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
HLN Yearly Dividends per shareHLN Yearly Dividends per shareYearly Dividends per share 2023 2024 2025 0.01 0.02 0.03 0.04 0.05

5.3 Sustainability

DPN/A
EPS Next 2Y8.99%
EPS Next 3Y8.81%
HLN Yearly Income VS Free CF VS DividendHLN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

HALEON PLC-ADR

NYSE:HLN (6/12/2025, 8:04:00 PM)

After market: 11.01 0 (0%)

11.01

+0.1 (+0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-30 2025-04-30
Earnings (Next)N/A N/A
Inst Owners49.58%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap49.54B
Analysts79.23
Price Target11.96 (8.63%)
Short Float %0.44%
Short Ratio1.22
Dividend
Industry RankSector Rank
Dividend Yield 1.64%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years1
Div Non Decr Years1
Ex-Date04-24 2025-04-24 (0.046)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.58%
Min EPS beat(2)-1.92%
Max EPS beat(2)7.08%
EPS beat(4)3
Avg EPS beat(4)3.76%
Min EPS beat(4)-1.92%
Max EPS beat(4)7.54%
EPS beat(8)4
Avg EPS beat(8)-10.37%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.51%
Min Revenue beat(2)-5.38%
Max Revenue beat(2)-1.64%
Revenue beat(4)0
Avg Revenue beat(4)-3.11%
Min Revenue beat(4)-5.38%
Max Revenue beat(4)-1.64%
Revenue beat(8)1
Avg Revenue beat(8)-2.55%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.29%
PT rev (3m)10.87%
EPS NQ rev (1m)0.22%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.22%
EPS NY rev (3m)-1.57%
Revenue NQ rev (1m)-0.47%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.92%
Valuation
Industry RankSector Rank
PE 22.02
Fwd PE 20.36
P/S 3.25
P/FCF 18.4
P/OCF 15.85
P/B 2.26
P/tB N/A
EV/EBITDA 16.32
EPS(TTM)0.5
EY4.54%
EPS(NY)0.54
Fwd EY4.91%
FCF(TTM)0.6
FCFY5.44%
OCF(TTM)0.69
OCFY6.31%
SpS3.39
BVpS4.88
TBVpS-3.03
PEG (NY)2.43
PEG (5Y)1.25
Profitability
Industry RankSector Rank
ROA 4.2%
ROE 8.92%
ROCE 8.4%
ROIC 6.11%
ROICexc 6.63%
ROICexgc 4145.85%
OM 21.31%
PM (TTM) 12.84%
GM 60.75%
FCFM 17.65%
ROA(3y)3.44%
ROA(5y)3.54%
ROE(3y)7.24%
ROE(5y)6.28%
ROIC(3y)6.15%
ROIC(5y)5.77%
ROICexc(3y)6.57%
ROICexc(5y)6.04%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)8.5%
ROCE(5y)8.01%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y12.56%
ROICexc growth 5Y14.99%
OM growth 3Y-0.45%
OM growth 5Y3.75%
PM growth 3Y-4.12%
PM growth 5Y10.69%
GM growth 3Y0.43%
GM growth 5Y0.58%
F-Score6
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF 5.11
Debt/EBITDA 3.18
Cap/Depr 98.15%
Cap/Sales 2.83%
Interest Coverage 6.65
Cash Conversion 84.66%
Profit Quality 137.52%
Current Ratio 0.98
Quick Ratio 0.78
Altman-Z 2.42
F-Score6
WACC7.83%
ROIC/WACC0.78
Cap/Depr(3y)107.06%
Cap/Depr(5y)107.33%
Cap/Sales(3y)2.94%
Cap/Sales(5y)3.03%
Profit Quality(3y)156.45%
Profit Quality(5y)128.12%
High Growth Momentum
Growth
EPS 1Y (TTM)6.59%
EPS 3Y1.58%
EPS 5Y17.56%
EPS Q2Q%32.07%
EPS Next Y9.06%
EPS Next 2Y8.99%
EPS Next 3Y8.81%
EPS Next 5Y8.61%
Revenue 1Y (TTM)-0.61%
Revenue growth 3Y5.58%
Revenue growth 5Y5.78%
Sales Q2Q%-0.25%
Revenue Next Year0.74%
Revenue Next 2Y2.54%
Revenue Next 3Y3.21%
Revenue Next 5Y3.97%
EBIT growth 1Y4.68%
EBIT growth 3Y5.1%
EBIT growth 5Y9.75%
EBIT Next Year13.76%
EBIT Next 3Y8.96%
EBIT Next 5Y7.75%
FCF growth 1Y12.42%
FCF growth 3Y23.3%
FCF growth 5Y29.57%
OCF growth 1Y9.57%
OCF growth 3Y19.28%
OCF growth 5Y23.96%